Cellectis And Accelera (Nerviano Medical Sciences (NervianoMS)) Sign An Agreement To Complete Preclinical Studies Of Cellectis’ Lead Product Candidate UCART19
6/5/2014 12:47:32 PM
Cellectis (Paris:ALCLS), a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis’ advanced product candidate, UCART19. Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating B-cell leukemias and lymphomas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by